Nurix Therapeutics, Inc.NRIXNASDAQ
Loading
EBITDA Margin Over TimeContracting
Percentile Rank57
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

Latest
-305.99%
↓ 13% vs avg
Percentile
P57
Within normal range
Streak
1 yr
Consecutive growthContracting
Average
-270.56%
Historical baseline
PeriodValueYoY Change
TTM-305.99%+18.6%
2024-375.83%-94.3%
2023-193.45%+58.4%
2022-465.27%-19.4%
2021-389.57%-10.5%
2020-352.43%-451.5%
2019-63.90%-254.5%
2018-18.03%-